NCT05672537 is a Phase 2 clinical trial of Durvalumab in Durvalumab, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT05672537?

NCT05672537 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT05672537?

Interventions in NCT05672537: Durvalumab, Surgery, Gemcitabine, Cisplatin.

What condition does NCT05672537 study?

NCT05672537 studies Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis.

Is NCT05672537 still recruiting?

NCT05672537 is currently status unknown. Last updated 5 January 2023.

Last reviewed 2023-01-05 · How we verify

NCT05672537

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Status unknown Phase 2 Last updated 5 January 2023

What this trial tests

Phase 2 trial testing Durvalumab in Durvalumab in 70 participants. Status unknown.

Timeline

20 January 2023

Primary endpoint
31 December 2024

31 December 2025

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	20 January 2023
Primary completion	31 December 2024
Estimated completion	31 December 2025
Sites	1 location across China

Drugs / interventions tested

Durvalumab — full drug profile →
Surgery
Gemcitabine (gemcitabine) — full drug profile →
Cisplatin (cisplatin) — full drug profile →

Conditions studied

Durvalumab — all drugs for Durvalumab →
Intrahepatic Cholangiocarcinoma — all drugs for Intrahepatic Cholangiocarcinoma →
Gemcis — all drugs for Gemcis →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 75, any sex, with Durvalumab or Intrahepatic Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Current and Emerging Therapeutic Targets for the Treatment of Cholangiocarcinoma: An Updated Review.
Hadfield MJ, DeCarli K, Bash K, Sun G, et al · · 2023 · cited 12× · PMID 38203714 · DOI 10.3390/ijms25010543
Emerging Therapies in Management of Cholangiocarcinoma.
Speckart J, Rasmusen V, Talib Z, GnanaDev DA, et al · · 2024 · cited 8× · PMID 38339363 · DOI 10.3390/cancers16030613
Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma.
Heumann P, Albert A, Gülow K, Tümen D, et al · · 2024 · cited 4× · PMID 38730642 · DOI 10.3390/cancers16091690
Perioperative and palliative systemic treatments for biliary tract cancer.
Taghizadeh H, Dong Y, Gruenberger T, Prager GW. · · 2024 · cited 4× · PMID 38559612 · DOI 10.1177/17588359241230756
Management of intrahepatic cholangiocarcinoma: a review for clinicians.
Colangelo M, Di Martino M, Polidoro MA, Forti L, et al · · 2025 · cited 3× · PMID 39867595 · DOI 10.1093/gastro/goaf005
New perspectives in biology-driven treatment of cholangiocarcinoma: from oncological resectability to genetic breakthroughs and AI-powered imaging.
Viganò L, Risi L, Ammirabile A. · · 2025 · PMID 40893768 · DOI 10.21037/hbsn-2025-261
Neoadjuvant immunotherapy for resectable primary liver cancer (Review).
Deng Q, He M, Zhang L, Wu Y. · · 2025 · PMID 40762016 · DOI 10.3892/ol.2025.15204

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Durvalumab

Currently open trials in the same condition.

NCT06999694 — Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC · Phase 2 · recruiting
NCT06999707 — Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC · Phase 2 · recruiting
NCT06859684 — Hepatic Arterial Infusion Chemotherapy (HAIC) Combined With Durvalumab and Lenvatinib in Patients With Locally Advanced · Phase 2 · recruiting

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05672537 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 5 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05672537.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing